Abstract
Hepatitis B virus (HBV) whole genome sequencing (WGS) is currently limited as the DNA viral loads (VL) of many clinical samples are below the threshold required to generate full genomes using current sequencing methods. We developed two pan-genotypic viral enrichment methods, using probe-based capture and tiled amplicon PCR (HEP-TILE) for HBV WGS. We demonstrate using mock samples that both enrichment methods are pan-genotypic (genotypes A-J). Using clinical samples, we demonstrate that HEP-TILE amplification successfully amplifies full genomes at the lowest HBV VL tested (30 IU/ml), and the PCR products can be sequenced using both Nanopore and Illumina platforms. Probe-based capture with Illumina sequencing required VL >300,000 IU/ml to generate full length HBV genomes. The capture-Illumina and HEP-TILE-Nanopore pipelines had consensus sequencing accuracy of 100% in mock samples with known DNA sequences. Together, these protocols will facilitate the generation of HBV sequence data, enabling a more accurate and representative picture of HBV molecular epidemiology, cast light on persistence and pathogenesis, and enhance understanding of the outcomes of infection and its treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded in whole, or in part, by the Wellcome Trust [220549/Z/20/Z, 206298/B/17/Z, 220171/Z/20/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this Submission. SFL is funded by a Wellcome Doctoral Training Fellowship (grant number 220549/Z/20/Z). JQ/NL/CK are funded by the Wellcome Trust through the ARTIC Network Collaborative Award (Grant number 206298/B/17/Z). MAA is supported by a Sir Henry Dale Fellowship jointly funded by the Royal Society and Wellcome Trust (220171/Z/20/Z). PCM has funding from the UCLH NIHR Biomedical Research Centre, and core funding from the Francis Crick Institute (ref CC2223).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK patients: Oxford Research Ethics Committee A (ref. 09/H0604/20) South Africa / Stellenbosch patients: Stellenbosch University (ref. N17/01/013) and OxTREC (ref 1-18) South Africa / Bloemfontein patients: University of the Free State (ref. UFS-HSD2018/0193-0001) and OxTREC (ref. 1-18) Uganda patients: Uganda Virus Research Institute Research and Ethics Committee (ref. GC/127/19/04/711), Uganda National Council for Science and Technology, and Oxford Tropical Research Ethics Committee (ref 50-18)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained or linked in the manuscript
